中国医院用药评价与分析2025，Vol.25Issue(3)：319-324,6.DOI:10.14009/j.issn.1672-2124.2025.03.015
瘀血痹片(胶囊)联合基础疗法治疗慢性肌肉骨骼疼痛的有效性与安全性的Meta分析
Meta-Analysis on Efficacy and Safety of Yuxuebi Tablets(Capsules)Combined with Basic Therapy in the Treatment of Chronic Musculoskeletal Pain
摘要
Abstract
OBJECTIVE:To systematically review the clinical efficacy and safety of Yuxuebi tablets(capsules)combined with basic therapy in the treatment of chronic musculoskeletal pain(CMP).METHODS:PubMed,Web of Science,Embase,the Cochrane Library,CNKI,VIP,Wanfang Data,and CBM were retrieved to clinical randomized controlled trials(RCT)of Yuxuibi tablets(capsules)in the treatment of CMP as of Aug.4th,2024.Cochrane risk assessment tool was used to evaluate the quality of literature that met the inclusion criteria,and RevMan 5.3 software was used for Meta-analysis.RESULTS:A total of 8 RCT were enrolled,including 854 cases of patients.Meta-analysis showed that compared with basic therapy alone,Yuxuebi tablets(capsules)combined with basic therapy could significantly improve the total effective rate(OR=3.31,95%CI=2.13-5.13,P<0.000 01),reduce the visual analog score and relieve pain(MD=-2.07,95%CI=-2.52--1.62,P<0.000 01),increase the Lysholm score and enhance the joint function(MD=9.37,95%CI=7.10-11.64,P<0.000 01),increase the ADL score and improve the quality of daily life(MD=15.16,95%CI=9.79-20.52,P<0.000 01),inhibit the serum inflammatory cytokines interleukin 1(MD=-0.54,95%CI=-0.83--0.26,P=0.000 1),interleukin 8(MD=-20.92,95%CI=-21.93--19.91,P<0.000 01),tumor necrosis factor α(MD=-16.74,95%CI=-22.60--10.87,P<0.000 01),C-reactive protein(MD=-5.83,95%CI=-8.59--3.08,P<0.000 1),the differences were statistically significant.In terms of treatment safety,there was no significant difference in the incidence of adverse drug reactions between two groups(RR=0.63,95%CI=0.21-1.90,P=0.41).CONCLUSIONS:The efficacy of Yuxuebi tablets(capsules)combined with basic therapy in the intervention of CMP is better than that of basic therapy alone.However,due to the limited included studies and low literature quality,it is still necessary to carry out large-sample and high-quality RCT to increase the strength of evidence.关键词
瘀血痹片(胶囊)/慢性肌肉骨骼疼痛/类风湿关节炎/膝骨关节炎/Meta分析Key words
Yuxuebi tablets(capsules)/Chronic musculoskeletal pain/Rheumatoid arthritis/Knee osteoar-thritis/Meta-analysis分类
医药卫生引用本文复制引用
刘莹,张国鑫,王文丽,黄奥晴,朱春燕,林娜..瘀血痹片(胶囊)联合基础疗法治疗慢性肌肉骨骼疼痛的有效性与安全性的Meta分析[J].中国医院用药评价与分析,2025,25(3):319-324,6.基金项目
国家"重大新药创制"科技重大专项(No.2019ZX09731-002) （No.2019ZX09731-002）
中国中医科学院中药研究所技术研发项目(No.20210701,No.20231019) （No.20210701,No.20231019）
